About this trial
Transcranial temporal interference stimulation (TIS) is an emerging novel tool for non-invasive transcranial brain stimulation that holds the potential for focal and steerable neuromodulation, and the possibility to stimulate focally at depth. TIS involves combining two high frequency waveforms to create a waveform with a "beat" frequency that is physiological relevant for neuromodulation. Successful applications to deep brain targets as well as steerability of the stimulation focus have been demonstrated in mice. Numerous recent investigations in humans have shown great clinical potential for this technology, however several questions about the basic mechanism of TIS action remain. The investigators will apply TIS to the motor cortex of humans and use established transcranial magnetic stimulation techniques to assess cortical excitability in relation to the phase of the TIS waveform. Using TMS, the investigators will i) validate that effects of TIS are due to the "beat" frequency and not the high frequency carrier signal, ii) evaluate the effect of the TIS carrier frequency, and iii) evaluate that whether changes in corticospinal excitability outlast the period of stimulation. Knowledge gained from this experiment will provide a basis for the future use of TIS for clinical applications, including informing parameter optimization.
Eligibility criteria
Qualifiers
Free of neurological or orthopedic conditions that may impact the ability to participate.
Right-hand dominant (self-reported)
Aged 18-65 years
Disqualifiers
Ferromagnetic metal implants in the brain/skull or elsewhere (dental implants excluded).
Any implanted electronic device (e.g. cardiac pacemaker, cochlear implant, deep brain stimulator, medication infusion pump; vagal nerve stimulator)
Diseased or damaged skin on face or scalp
History of migraines, fainting, seizures/epilepsy, or psychiatric illness
Trial design
Treatments tested in this trial
- transcranial Temporal Interference Stimulation
Treatment groups
6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Northeastern University
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborator